Geulah Livshits
Stock Analyst at Chardan Capital
(4.07)
# 514
Out of 5,135 analysts
248
Total ratings
45.56%
Success rate
15.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $74 → $76 | $53.17 | +42.94% | 17 | Feb 17, 2026 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $17 | $6.28 | +170.70% | 14 | Jan 13, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $12 | $4.58 | +162.01% | 17 | Jan 6, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $26 | $9.48 | +174.26% | 14 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $110 → $174 | $79.92 | +117.72% | 6 | Dec 16, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $9 → $8 | $0.63 | +1,167.43% | 14 | Dec 12, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 → $13 | $0.86 | +1,414.62% | 11 | Dec 9, 2025 | |
| IMTX Immatics | Maintains: Buy | $25 | $9.93 | +151.76% | 3 | Nov 24, 2025 | |
| IMRX Immuneering | Maintains: Buy | $20 | $5.12 | +290.63% | 15 | Nov 13, 2025 | |
| PASG Passage Bio | Maintains: Buy | $6 → $21 | $8.82 | +138.23% | 6 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $3.31 | +171.90% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $26 | $12.22 | +112.77% | 17 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $2.62 | +548.85% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $5.50 | +172.73% | 9 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $216 → $220 | $287.84 | -23.57% | 14 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $3.31 | +232.33% | 22 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.46 | +653.42% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $1.93 | +210.88% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.74 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.58 | +440.90% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.96 | +305.41% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $43.93 | +373.48% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $0.68 | +2,259.88% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $8.04 | +1,019.40% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.41 | +17.30% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $22.69 | -20.67% | 1 | Oct 27, 2020 |
CRISPR Therapeutics AG
Feb 17, 2026
Maintains: Buy
Price Target: $74 → $76
Current: $53.17
Upside: +42.94%
Lexeo Therapeutics
Jan 13, 2026
Maintains: Buy
Price Target: $17
Current: $6.28
Upside: +170.70%
Taysha Gene Therapies
Jan 6, 2026
Maintains: Buy
Price Target: $12
Current: $4.58
Upside: +162.01%
4D Molecular Therapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $26
Current: $9.48
Upside: +174.26%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $110 → $174
Current: $79.92
Upside: +117.72%
Tenaya Therapeutics
Dec 12, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $0.63
Upside: +1,167.43%
Senti Biosciences
Dec 9, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $0.86
Upside: +1,414.62%
Immatics
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $9.93
Upside: +151.76%
Immuneering
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $5.12
Upside: +290.63%
Passage Bio
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $8.82
Upside: +138.23%
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $3.31
Upside: +171.90%
Nov 7, 2025
Maintains: Buy
Price Target: $48 → $26
Current: $12.22
Upside: +112.77%
Nov 6, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $2.62
Upside: +548.85%
Nov 4, 2025
Maintains: Buy
Price Target: $15
Current: $5.50
Upside: +172.73%
Nov 4, 2025
Maintains: Buy
Price Target: $216 → $220
Current: $287.84
Upside: -23.57%
Oct 14, 2025
Maintains: Buy
Price Target: $11
Current: $3.31
Upside: +232.33%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.46
Upside: +653.42%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.93
Upside: +210.88%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.74
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.58
Upside: +440.90%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $2.96
Upside: +305.41%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $43.93
Upside: +373.48%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $0.68
Upside: +2,259.88%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $8.04
Upside: +1,019.40%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.41
Upside: +17.30%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $22.69
Upside: -20.67%